Three Investigational Treatments for Lung Cancer, Huntington’s Disease and Alzheimer's Gain Innovation Passports

Three investigational treatments for serious diseases have been awarded Innovation Passports through the UK’s Innovative Licensing and Access Pathway (ILAP). The ILAP is a unique end-to-end access pathway that enables developers to work with the national health system, the regulator, and health technology assessment bodies from early stages of clinical development.

The Innovation Passports have been awarded to a chemical siRNA for the treatment of Huntington’s disease, a chemical small molecule oncology therapy for first-line Non-Small Cell Lung Cancer (NSCLC), and a chemical Antisense Oligonucleotide (ASO) for the treatment of early Alzheimer’s disease.

Huntington’s disease is a rare, inherited, and ultimately fatal neurodegenerative disease. NSCLC is the most common type of lung cancer, with around 50,200 people diagnosed in the UK each year. Alzheimer’s disease is a progressive neurodegenerative disorder and the most common cause of dementia, affecting an estimated 982,000 people in the UK in 2024.

The ILAP is a partnership between the Medicines and Healthcare products Regulatory Agency (MHRA), NHS England, the UK Health Technology Assessment (HTA) bodies, and the Department of Health Northern Ireland. Applications for the next round of Innovation Passports are open until 11 February 2027.